Danish biotechnology company Zealand Pharma said on Thursday it expected to initiate a phase 2b trial with its obesity ...

Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...

The Denmark-based drug maker Zealand Pharma said Tuesday that its experimental weight-loss drug could help patients lose ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

Obesity caused by a lifestyle of moving less and eating more is a prime factor contributing to Type 2 diabetes. Is the answer new weight loss drugs?

Danish company Novo Nordisk has a market cap larger than the entire country's GDP. As it grows, it's having an impact on ...

Novo's development chief, Martin Holst Lange, has shown optimism about the drug's promise, though he refrained from making ...

The ‘Ozempic drug,’ semaglutide, has been found to reduce moderately severe pain caused by knee osteoarthritis and improve ...

As the battle against obesity and diabetes heats up, two new superstars are entering the ring in Spain - Mounjaro (also known ...

It broke open a market that could reach $130 billion by 2030 and has a cultural reach broader than any new drug since Viagra. Yet to keep its lead in the red-hot field of obesity, Novo must prove ...

Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most ...